UCB (OTCMKTS:UCBJF) Shares Gap Up – Still a Buy?

UCB SA (OTCMKTS:UCBJF) gapped up before the market opened on Thursday. The stock had previously closed at $314.48, but opened at $333.39. UCB shares last traded at $333.39, with a volume of 46 shares traded.

Analyst Upgrades and Downgrades

UCBJF has been the subject of several recent analyst reports. Stephens restated an “overweight” rating on shares of UCB in a report on Wednesday, October 21st. Piper Sandler reiterated a “neutral” rating on shares of UCB in a report on Wednesday, July 22nd. Finally, Jefferies Financial Group raised shares of UCB to a “hold” rating in a research report on Monday, August 3rd. Five research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy”.

UCB Stock Up 3.3%

The company has a 50-day moving average price of $263.88 and a two-hundred day moving average price of $286.33. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

UCB Company Profile

UCB is a Belgian biopharmaceutical company founded in 1928 and headquartered in Brussels. It discovers, develops and commercializes medicines, with a focus on neurological and immunological conditions. Its products include treatments for epilepsy, such as Keppra, Briviact and Nayzilam, as well as medicines for inflammatory diseases, including Cimzia and Bimzelx. UCB also develops therapies for other serious conditions, including myasthenia gravis. The company serves patients and healthcare providers in markets around the world.